Cityscape nct03563716
WebIn the phase II CITYSCAPE study (NCT03563716), atezo + tira was well tolerated and improved objective response rate (ORR) compared with atezo alone in 1L pts with metastatic PD-L1+ NSCLC; with greater benefit in the … WebCITYSCAPE (NCT03563716) is the first randomised Phase II study of an anti-TIGIT antibody; the combination of TA showed clinically meaningful improvement in ORR and PFS compared with PA in patients (pts) with metastatic PD-L1+ NSCLC. Here we present updated PFS, OS, and PROs.
Cityscape nct03563716
Did you know?
WebAsco: Combination Of Tiragolumab And Atezolizumab. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Intervention : Tiragolumab (tira) plus …
WebCITYSCAPE (NCT03563716) is the first randomised Phase II study of an anti-TIGIT antibody; the combination of TA showed clinically meaningful improvement in ORR and PFS compared with PA in patients (pts) with metastatic PD-L1+ NSCLC. ... NCT03563716. Editorial acknowledgement. Medical writing support for the development of this abstract, … WebDec 10, 2024 · CITYSCAPE is a global Phase II, randomized and blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) compared with Tecentriq alone in 135 …
WebIn the phase II CITYSCAPE study (NCT03563716), atezo + tira showed an improved objective response rate (ORR) and a similar safety profile compared with atezo alone in 1L pts with metastatic PD-L1+ NSCLC. SKYSCRAPER-09 (NCT04665843) aims to evaluate the efficacy and safety of the chemo-free regimen of atezo + tira and atezo + placebo in … WebJan 5, 2024 · The phase II CITYSCAPE (NCT03563716) studied tiragolumab in combination with atezolizumab in PD-L1 positive advanced/metastatic NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. 25 A total of 135 patients were randomized to the combination tiragolumab 600 mg plus atezolizumab …
WebDec 10, 2024 · CITYSCAPE is a global phase II, randomised and blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) compared with Tecentriq alone in 135 …
WebDec 10, 2024 · CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer ... (NCT02794571; NCT03563716 ... pakenham lions football clubWebSep 23, 2024 · Based on preliminary efficacy and safety observed in the phase 1a/1b trial described, the phase 2 CITYSCAPE (NCT03563716) trial was initiated to examine atezolizumab, alone or combined with tiragolumab, for firstline treatment of 135 patients with locally advanced or metastatic NSCLC with measurable disease. pakenham medical clinic blood testWebSep 27, 2024 · September 27, 2024. The Goose Creek Village shopping center in Ashburn is getting not one, but two new restaurants. It’s part of a burst of exciting activity for the … sum bridges constructionWeb• In the phase II CITYSCAPE study (NCT03563716), atezolizumab + tiragolumab showed an improved ORR and PFS and a similar safety profile compared with placebo + atezolizumab in 1L patients with metastatic PD-L1+ NSCLC, with a greater magnitude of improvement observed in the PD-L1 TPS ≥50% subgroup9 sumbuck concertWebJan 6, 2024 · The FDA’s designation was based on promising safety and efficacy data from the CITYSCAPE Phase 2 clinical trial (NCT03563716), ... CITYSCAPE is one of the trials exploring the rationale of combining tiragolumab with Tecentriq, an antibody-based immunotherapy also developed by Genentech that inhibits PD-L1, a protein produced by … sumb sweatshirtWebJan 5, 2024 · The first anti-TIGIT molecule to be granted this designation, tiragolumab was granted BTD based on data from the global, double-blind, randomized phase 2 … sumbro x-force 9mm fmj 124 grain reviewWebAbstract. Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III … sum bucha